The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Expression and mutational analysis of MET in human solid cancers
Open accessAbstract
MET receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) regulate a variety of cellular functions, many of which can be dysregulated in human cancers. Activated MET signaling can lead to cell motility and scattering, angiogenesis, proliferation, branching morphogenesis, invasion, and eventual metastasis. We performed systematic analysis of the expression of the MET receptor and its ligand HGF in tumor tissue microarrays (TMA) from human solid cancers. Standard immunohistochemistry (IHC) and a computerized automated scoring system were used. DNA sequencing for MET mutations in both nonkinase and kinase domains was also performed. MET was differentially overexpressed in human solid cancers. The ligand HGF was widely expressed in both tumors, primarily intratumoral, and nonmalignant tissues. The MET/HGF likely is functional and may be activated in autocrine fashion in vivo. MET and stem cell factor (SCF) were found to be positively stained in the bronchioalevolar junctions of lung tumors. A number of novel mutations of MET were identified, particularly in the extracellular semaphorin domain and the juxtamembrane domain. MET‐HGF pathway can be assayed in TMAs and is often overexpressed in a wide variety of human solid cancers. MET can be activated through overexpression, mutation, or autocrine signaling in malignant cells. Mutations in the nonkinase regions of MET might play an important role in tumorigenesis and tumor progression. MET would be an important therapeutic antitumor target to be inhibited, and in lung cancer, MET may represent a cancer early progenitor cell marker. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“Various parameters of predictor of response to kinase inhibitors, especially the EGFR targeting gefitinib and erlotinib, have been under rigorous testing (Bell et al., 2005; Eberhard et al., 2005; Haber et al., 2005; Kobayashi et al., 2005; Pao et al., 2005; Shepherd et al., 2005).”
BackgroundIdentification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer
Kim, C. F. B., Jackson, E. L., Woolfenden, A. E., Lawrence, S., Babar, I., Vogel, S., Crowley, D., Bronson, R. T., & Jacks, T. (2005) · Cell · doi:10.1016/j.cell.2005.03.032 · Cited by 2,195
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Schmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Jänne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,461
Significance of CD90+ Cancer Stem Cells in Human Liver Cancer
Yang, Z. F., Ho, D. W., Ng, M. N., Lau, C. K., Yu, W. C., Ngai, P., Chu, P. W. K., Lam, C. T., Poon, R. T. P., & Fan, S. T. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.013 · Cited by 1,188
Hope, K. J., Jin, L., & Dick, J. E. (2004) · Nature Immunology · doi:10.1038/ni1080 · Cited by 968
Side Population in Human Lung Cancer Cell Lines and Tumors Is Enriched with Stem-like Cancer Cells
Ho, M. M., Ng, A. V., Lam, S., & Hung, J. Y. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3557 · Cited by 947
Bell, D. W., Lynch, T. J., Haserlat, S. M., Harris, P. L., Okimoto, R. A., Brannigan, B. W., Sgroi, D. C., Muir, B., Riemenschneider, M. J., Iacona, R. B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7078 · Cited by 601
Ma, P. C., Jagadeeswaran, R., Jagadeesh, S., Tretiakova, M. S., Nallasura, V., Fox, E. A., Hansen, M., Schaefer, E., Naoki, K., Lader, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2650 · Cited by 576
Self-citationc-Met: Structure, functions and potential for therapeutic inhibition
Ma, P. C., Maulik, G., Christensen, J., & Salgia, R. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023768811842 · Cited by 504
Self-citationNovel mutations of the MET proto-oncogene in papillary renal carcinomas
Schmidt, L., Junker, K., Nakaigawa, N., Kinjerski, T., Weirich, G., Miller, M., Lubensky, I., Neumann, H. P., Brauch, H., Decker, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202547 · Cited by 497
Christensen, J. G., Schreck, R., Burrows, J., Kuruganti, P. A., Chan, E., Le, P., Chen, J., Wang, X., Ruslim, L., Blake, R. A., et al. (2003) · PubMed · Cited by 497
Self-citationSmolen, G. A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald, H., Kim, W. J., Okimoto, R. A., Bell, D. W., Sgroi, D. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508776103 · Cited by 485
Self-citationMa, P. C., Kijima, T., Maulik, G., Fox, E. A., Sattler, M., Griffin, J. D., Johnson, B. E., & Salgia, R. (2003) · PubMed · Cited by 454
Self-citationMammary stem cells, self-renewal pathways, and carcinogenesis
Liu, S., Dontu, G., & Wicha, M. S. (2005) · Breast Cancer Research · doi:10.1186/bcr1021 · Cited by 446
Jänne, P. A., Engelman, J. A., & Johnson, B. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.985 · Cited by 405
Lee, J. C., Vivanco, I., Beroukhim, R., Huang, J. H. Y., Feng, W. L., DeBiasi, R. M., Yoshimoto, K., King, J. C., Nghiemphu, P., Yuza, Y., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030485 · Cited by 367
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
Di Renzo, M. F., Olivero, M., Martone, T., Maffe, A., Maggiora, P., De Stefani, A., Valente, G., Giordano, S., Cortesina, G., & Comoglio, P. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203455 · Cited by 332
Lung Cancer Cell Lines Harboring MET Gene Amplification Are Dependent on Met for Growth and Survival
Lutterbach, B., Zeng, Q., Davis, L. J., Hatch, H., Hang, G., Kohl, N. E., Gibbs, J. B., & Pan, B.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3495 · Cited by 320
Wang, S., Garcia, A. J., Wu, M., Lawson, D. A., Witte, O. N., & Wu, H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510652103 · Cited by 308
Burger, P. E., Xiong, X., Coetzee, S., Salm, S. N., Moscatelli, D., Goto, K., & Wilson, E. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502761102 · Cited by 261
Sawada, K., Radjabi, A. R., Shinomiya, N., Kistner, E., Kenny, H., Becker, A. R., Turkyilmaz, M. A., Salgia, R., Yamada, S. D., Vande Woude, G. F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1147 · Cited by 258
Self-citationJi, H., Zhao, X., Yuza, Y., Shimamura, T., Li, D., Protopopov, A., Jung, B. L., McNamara, K., Xia, H., Glatt, K. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510284103 · Cited by 257
Takeuchi, H., Bilchik, A. J., Saha, S., Turner, R. R., Wiese, D., Tanaka, M., Kuo, C. T., Wang, H. J., & Hoon, D. S. �. (2003) · PubMed · Cited by 232
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik, G., Kijima, T., Ma, P. C., Ghosh, S. K., Lin, J. J., Shapiro, G. I., Schaefer, E., Tibaldi, E. V., Johnson, B. E., & Salgia, R. (2002) · PubMed · Cited by 228
Self-citationOverexpression of theMET/HGF receptor in ovarian cancer
Di Renzo, M. F., Olivero, M., Katsaros, D., Crepaldi, T., Gaglia, P., Zola, P., Sismondi, P., & Comoglio, P. M. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910580507 · Cited by 212
The Sema domain of Met is necessary for receptor dimerization and activation
Kong-Beltran, M., Stamos, J., & Wickramasinghe, D. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.013 · Cited by 209
Olivero, M., Rizzo, M., Madeddu, R., Casadio, C., Pennacchietti, S., Nicotra, M., Prat, M., Maggi, G., Arena, N., Natali, P., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.646 · Cited by 199
Functional Analysis of c-Met/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma
Jagadeeswaran, R., Ma, P. C., Seiwert, T. Y., Jagadeeswaran, S., Zumba, O., Nallasura, V., Ahmed, S., Filiberti, R., Paganuzzi, M., Puntoni, R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-4567 · Cited by 198
Self-citationc-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases
Zeng, Z.-S., Weiser, M. R., Kuntz, E., Chen, C.-T., Khan, S. A., Forslund, A., Nash, G. M., Gimbel, M., Yamaguchi, Y., Culliford, A. T., et al. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.049 · Cited by 180
c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma
Puri, N., Ahmed, S., Janamanchi, V., Tretiakova, M., Zumba, O., Krausz, T. N., Jagadeeswaran, R., & Salgia, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0776 · Cited by 155
Self-citationFischer, J., Palmedo, G., von Knobloch, R., Bugert, P., Prayer-Galetti, T., Pagano, F. C., & Kovács, G. (1998) · Oncogene · doi:10.1038/sj.onc.1201983 · Cited by 141
Selective Targeting of Cancer Stem Cells: A New Concept in Cancer Therapeutics
Körkaya, H., & Wicha, M. S. (2007) · BioDrugs · doi:10.2165/00063030-200721050-00002 · Cited by 126
A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin
Ma, P. C., Schaefer, E., Christensen, J. G., & Salgia, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1708 · Cited by 124
Self-citationMolecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR InhibitorsPreprint
Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., Lynch, T. J., & Settleman, J. E. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.043 · Cited by 114
Graveel, C., Su, Y., Koeman, J. M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407651101 · Cited by 108
Ocal, I. T., Dolled-Filhart, M. P., D'Aquila, T. G., et al. (2003) · Cancer · doi:10.1002/cncr.11335 · Cited by 103
Soh, J., Toyooka, S., Ichihara, S., Asano, H., Kobayashi, N., Suehisa, H., Otani, H., Yamamoto, H., Ichimura, K., Kiura, K., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318168d20a · Cited by 80
Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis?
Wong, A. S. T., Pelech, S., Woo, M. M. M., Yim, G., Rosen, B. P., Ehlen, T. G., Leung, P. C. K., & Auersperg, N. (2001) · Oncogene · doi:10.1038/sj.onc.1204253 · Cited by 77
Garcia, S., Dalès, J.-P., Jacquemier, J. D., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603569 · Cited by 41
Cited by
Targeting MET in cancer: rationale and progress
Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3205 · Cited by 1,423
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Drilon, A., Cappuzzo, F., Ou, S.-H. I., & Camidge, D. R. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.014 · Cited by 389
c-MET as a potential therapeutic target and biomarker in cancer
Sierra, J. R., & Tsao, M.-S. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011422557 · Cited by 365
Seiwert, T. Y., Jagadeeswaran, R., Faoro, L., Janamanchi, V., Nallasura, V., El Dinali, M., Yala, S., Kanteti, R., Cohen, E. E. W., Lingen, M. W., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2881 · Cited by 269
Self-citationHGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
Fu, J., Su, X., Li, Z., Deng, L., Liu, X., Feng, X., & Peng, J. (2021) · Oncogene · doi:10.1038/s41388-021-01863-w · Cited by 235
Metadata
- Authors
- Ma, P. C., Tretiakova, M. S., MacKinnon, A. C., Ramnath, N., Johnson, C., Dietrich, S., Seiwert, T., Christensen, J. G., Jagadeeswaran, R., Krausz, T., Vokes, E. E., Husain, A. N., & Salgia, R.
- Venue
- Genes, Chromosomes and Cancer
- Publisher
- Wiley
- Published
- 2008-08-15
- Volume
- 47
- Issue
- 12
- Pages
- 1025-1037
- ISSN
- 1045-2257 (ISSN-L)
- 1098-2264
- OpenAlex
- W1994912526
- Cited by
- 300
- References
- 44
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.